Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-Current Assets for 11 consecutive years, with $314.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 42.95% to $314.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 17.99% decrease, with the full-year FY2025 number at $314.4 million, down 42.95% from a year prior.
  • Non-Current Assets was $314.4 million for Q4 2025 at Intellia Therapeutics, down from $343.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $551.2 million in Q4 2024 to a low of $115.8 million in Q1 2021.
  • A 5-year average of $358.2 million and a median of $362.7 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 1129.61% in 2021, then crashed 56.65% in 2022.
  • Intellia Therapeutics' Non-Current Assets stood at $525.2 million in 2021, then crashed by 42.24% to $303.3 million in 2022, then fell by 0.22% to $302.6 million in 2023, then surged by 82.11% to $551.2 million in 2024, then crashed by 42.95% to $314.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Non-Current Assets are $314.4 million (Q4 2025), $343.3 million (Q3 2025), and $402.9 million (Q2 2025).